Neovacs S.A.
Neovacs will attend Société Générale’s ‘Healthcare & Biotechnology Conference’ for the second time on 24 September 2014
Neovacs S.A. / Key word(s): Conference
Neovacs will attend Société Générale’s “Healthcare & Biotechnology Conference” for the second time on 24 September 2014
Paris, 23 September 2014 – Neovacs (Alternext Paris: ALNEV, FR0004032746), a leader in active immunotherapies for the treatment of autoimmune diseases, will return to the “Healthcare & Biotechnology Conference” organized by Société Générale on Wednesday, 24 September. Miguel Sieler, Neovacs’ CEO, will meet with investors to explain the innovative Kinoid technology, the current status of clinical developments, the outlook for its pre-clinical portfolio and the company’s strategy for the future. “We are very happy and flattered to be invited to this prestigious event, which enables us to meet major investors fully knowledgeable about the biotech field and capable of appreciating the risks and opportunities offered by sector companies,” explains Miguel Sieler before adding: “Our attendance at this event is the natural continuation of the investor meetings we have held since May as part of our roadshow, which included Frankfort, Munich, Amsterdam and Hong Kong, as well as New York last June as part of French Biotech Day organised by France Biotech.” About Neovacs Press & Financial Communication France – Publicis 23.09.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | Neovacs S.A. | |
3-5, Impasse Reille | ||
75014 Paris | ||
France | ||
Phone: | +33 (0)1 53 10 93 00 | |
Fax: | +33 (0)1 53 10 93 03 | |
E-mail: | www.neovacs.fr | |
Internet: | info@neovacs.fr | |
ISIN: | FR0004032746 | |
WKN: | A1CVKR | |
Listed: | Freiverkehr in Stuttgart; Frankfurt in Open Market | |
End of News | DGAP News-Service |
288220 23.09.2014 |